Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2026-05-13 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
6-K - Innate Pharma SA (0001598599) (Filer)
Foreign Filer Report
2026-05-13 English
Inside Information / News release on accounts, results
Earnings Release Classification · 92% confidence The document is a press release providing key highlights of the company’s first quarter 2026 business update and consolidated financial results (cash position, runway, revenue, liabilities) and announcing a conference call/webcast. It is not a full interim report with detailed financial statements, but an initial earnings announcement of quarterly results. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-13 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 90% confidence The document is a press release presenting Innate Pharma’s first quarter 2026 highlights: key financial metrics (Q1 revenue and cash position), R&D pipeline updates, and notice of a webcast/conference call. It does not contain full financial statements or detailed analysis, only summary results and operational highlights typical of an earnings release. Therefore, it should be classified as an Earnings Release. Q1 2026
2026-05-13 French
6-K - Innate Pharma SA (0001598599) (Filer)
Foreign Filer Report
2026-05-12 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 91% confidence The document is a press release disclosing the total number of shares and voting rights as required under French corporate and AMF regulations. It is a routine regulatory compliance announcement rather than an actual financial report, shareholder vote result, capital issuance, or other specific category. It does not present financial statements or detailed report content, nor is it a simple “publication announcement” of a different report. This fits the fallback category for general regulatory announcements and compliance notifications.
2026-05-12 French
Inside Information / Other news releases
Regulatory Filings Classification · 55% confidence The document is a press release disclosing the total number of shares outstanding and voting rights as of a given date, issued under French regulatory requirements (AMF and Code de Commerce). It is not reporting vote results (DVA), share capital changes (SHA), or a shareholding threshold crossing (MRQ). This is a routine regulatory announcement and falls into the fallback category for general regulatory filings.
2026-05-12 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.